Ibandronic acid

From Wikipedia, the free encyclopedia

Ibandronic acid
Systematic (IUPAC) name
[1-hydroxy-3-(methyl-pentyl-amino)-1-phosphono- propyl]phosphonic acid
Identifiers
CAS number	114084-78-5
ATC code	M05BA06
PubChem	60852
DrugBank	APRD00231
Chemical data
Formula	C9H23NO7P2
Mol. weight	319.229 g/mol
Pharmacokinetic data
Bioavailability	0.6%
Protein binding	90.9 to 99.5% (concentration-dependent)
Metabolism	Nil
Half life	10 to 60 hours
Excretion	Renal
Therapeutic considerations
Licence data	EU US
Pregnancy cat.	C(US)
Legal status	℞ Prescription only
Routes	Oral, intravenous

Ibandronic acid (INN) or ibandronate sodium (USAN), marketed under the trade names Boniva®, Bondronat® and Bonviva®, is a potent bisphosphonate drug used in the prevention and treatment of osteoporosis. It may also be used to treat hypercalcemia (elevated blood calcium levels).

[edit] Indications

Ibandronate is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Ibandronate was approved by the U.S. Food and Drug Administration (FDA) in May 2003 as a 2.5 mg daily treatment for postmenopausal osteoporosis. The basis for this approval was a 3-year, randomized, double-blind, placebo-controlled trial of 2,946 women with postmenopausal osteoporosis. Participants in this study received placebo or oral ibandronate either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses at the start of each 3-month interval). All study participants also received 500 mg of oral calcium and 400 international units of vitamin D daily. At the conclusion of the study, both doses significantly reduced the risk of new vertebral fractures by 50% to 52% when compared to placebo.

[edit] External links

• Boniva ® Osteoporosis Treatment

Bisphosphonates (M05A)edit
Nitrogenous:	Pamidronic acid, Alendronic acid, Ibandronic acid, Risedronic acid, Zoledronic acid
Non-nitrogenous:	Etidronic acid, Clodronic acid, Tiludronic acid